Related Experiment Video
Updated: Oct 16, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Covalent PROTACs: the best of both worlds?
1Oncology R&D, AstraZeneca Waltham USA neil.grimster@astrazeneca.com.
Abstract:
Covalent PROTACs combine the cutting edge research areas of targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs). This nascent field of research has already demonstrated several interesting findings, and holds an immense amount of potential to expand the druggable proteome. In this opinion, we present some of these intriguing early findings and discuss the potential advantages and disadvantages of this approach.
Insights
Covalent proteolysis targeting chimeras (PROTACs) merge targeted covalent inhibitors (TCIs) with PROTACs. This emerging field shows promise for expanding the druggable proteome, offering new therapeutic strategies.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Drug Discovery
Background:
- Covalent PROTACs integrate targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs).
- This novel approach aims to leverage the strengths of both TCIs and PROTACs for enhanced therapeutic outcomes.
Discussion:
- Exploration of early findings in covalent PROTAC research.
- Analysis of the potential advantages, such as prolonged target engagement and unique degradation profiles.
- Consideration of the disadvantages, including potential off-target toxicities and challenges in drug design.
Key Insights:
- Covalent PROTACs represent a nascent but promising area in drug discovery.
- The combination offers potential for overcoming resistance mechanisms and targeting challenging proteins.
- Early data suggests significant potential for expanding the druggable proteome.
Outlook:
- Future development of covalent PROTACs could lead to novel therapeutics.
- Further research is needed to fully understand and mitigate potential risks.
- This approach may redefine strategies for protein degradation-based therapies.
Related Concept Videos
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Protein-protein Interfaces
Cooperative Allosteric Transitions
Tagging and Fusion Proteins

